Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board's (PTAB's) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).

The patent interference was on remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) following the CAFC's May 2025 decision to affirm-in-part and vacate-in-part the PTAB's prior decision. This action by the PTAB is its third favorable decision determining that Broad was the first to invent the use of CRISPR/Cas9 for gene editing in eukaryotic cells, including human cells. CVC retains the right to appeal the decision to the CAFC.

The CRISPR/Cas9 patents at issue are exclusively licensed to Editas Medicine for the development and commercialization of CRISPR/Cas9-based medicines.

Other in-licensed patents from the Broad Institute, Harvard University, MIT, and other institutions covering CRISPR/Cas9, as well as those in-licensed patents from the Broad Institute and collaborators covering CRISPR/Cas12a, are not at issue in the interference and are unaffected by this decision.

Editas Medicine's foundational intellectual property includes issued patents covering fundamental aspects of both CRISPR/Cas12a and CRISPR/Cas9 gene editing in all human cells. Additionally, the Company holds a wide range of fundamental intellectual property directed to all the components of its gene editing platform including product-enabling and product-specific intellectual property covering the use of CRISPR/Cas12a and CRISPR/Cas9 for gene editing of human cells in the United States, Australia, Europe, Japan, China, and other jurisdictions.